Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 205

1.

Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3.

Aziz MH, Shen H, Maki CG.

Oncogene. 2011 Nov 17;30(46):4678-86. doi: 10.1038/onc.2011.185. Epub 2011 Jun 6.

2.

Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.

Ambrosini G, Sambol EB, Carvajal D, Vassilev LT, Singer S, Schwartz GK.

Oncogene. 2007 May 24;26(24):3473-81. Epub 2006 Dec 4.

PMID:
17146434
3.

Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma.

Drakos E, Thomaides A, Medeiros LJ, Li J, Leventaki V, Konopleva M, Andreeff M, Rassidakis GZ.

Clin Cancer Res. 2007 Jun 1;13(11):3380-7.

4.

HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function.

Lau LM, Nugent JK, Zhao X, Irwin MS.

Oncogene. 2008 Feb 7;27(7):997-1003. Epub 2007 Aug 13.

PMID:
17700533
6.

Disruption of p73-MDM2 binding synergizes with gemcitabine to induce apoptosis in HuCCT1 cholangiocarcinoma cell line with p53 mutation.

Zheng T, Wang J, Chen X, Meng X, Song X, Lu Z, Jiang H, Liu L.

Tumour Biol. 2010 Aug;31(4):287-95. doi: 10.1007/s13277-010-0035-7. Epub 2010 Apr 27.

PMID:
20422343
7.

Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21).

Drakos E, Singh RR, Rassidakis GZ, Schlette E, Li J, Claret FX, Ford RJ Jr, Vega F, Medeiros LJ.

Leukemia. 2011 May;25(5):856-67. doi: 10.1038/leu.2011.28. Epub 2011 Mar 11.

8.

Activation of p53 by nutlin-3a induces apoptosis and cellular senescence in human glioblastoma multiforme.

Villalonga-Planells R, Coll-Mulet L, Martínez-Soler F, Castaño E, Acebes JJ, Giménez-Bonafé P, Gil J, Tortosa A.

PLoS One. 2011 Apr 5;6(4):e18588. doi: 10.1371/journal.pone.0018588.

9.
10.

Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells.

Miyachi M, Kakazu N, Yagyu S, Katsumi Y, Tsubai-Shimizu S, Kikuchi K, Tsuchiya K, Iehara T, Hosoi H.

Clin Cancer Res. 2009 Jun 15;15(12):4077-84. doi: 10.1158/1078-0432.CCR-08-2955. Epub 2009 Jun 9.

11.

Novel roles for p53 in the genesis and targeting of tetraploid cancer cells.

Davaadelger B, Shen H, Maki CG.

PLoS One. 2014 Nov 7;9(11):e110844. doi: 10.1371/journal.pone.0110844. eCollection 2014.

12.

Pharmacological inhibition of Mdm2 triggers growth arrest and promotes DNA breakage in mouse colon tumors and human colon cancer cells.

Rigatti MJ, Verma R, Belinsky GS, Rosenberg DW, Giardina C.

Mol Carcinog. 2012 May;51(5):363-78. doi: 10.1002/mc.20795. Epub 2011 May 6.

13.

Mdm2 inhibition induces apoptosis in p53 deficient human colon cancer cells by activating p73- and E2F1-mediated expression of PUMA and Siva-1.

Ray RM, Bhattacharya S, Johnson LR.

Apoptosis. 2011 Jan;16(1):35-44. doi: 10.1007/s10495-010-0538-0.

PMID:
20812030
14.

MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63.

Gamble LD, Kees UR, Tweddle DA, Lunec J.

Oncogene. 2012 Feb 9;31(6):752-63. doi: 10.1038/onc.2011.270. Epub 2011 Jul 4.

15.

Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.

Van Maerken T, Ferdinande L, Taildeman J, Lambertz I, Yigit N, Vercruysse L, Rihani A, Michaelis M, Cinatl J Jr, Cuvelier CA, Marine JC, De Paepe A, Bracke M, Speleman F, Vandesompele J.

J Natl Cancer Inst. 2009 Nov 18;101(22):1562-74. doi: 10.1093/jnci/djp355. Epub 2009 Nov 10.

16.

Disruption of the MDM2-p53 interaction strongly potentiates p53-dependent apoptosis in cisplatin-resistant human testicular carcinoma cells via the Fas/FasL pathway.

Koster R, Timmer-Bosscha H, Bischoff R, Gietema JA, de Jong S.

Cell Death Dis. 2011 Apr 21;2:e148. doi: 10.1038/cddis.2011.33.

17.

Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells.

Michaelis M, Rothweiler F, Barth S, Cinatl J, van Rikxoort M, Löschmann N, Voges Y, Breitling R, von Deimling A, Rödel F, Weber K, Fehse B, Mack E, Stiewe T, Doerr HW, Speidel D, Cinatl J Jr.

Cell Death Dis. 2011 Dec 15;2:e243. doi: 10.1038/cddis.2011.129.

18.

Drug resistance to inhibitors of the human double minute-2 E3 ligase is mediated by point mutations of p53, but can be overcome with the p53 targeting agent RITA.

Jones RJ, Bjorklund CC, Baladandayuthapani V, Kuhn DJ, Orlowski RZ.

Mol Cancer Ther. 2012 Oct;11(10):2243-53. doi: 10.1158/1535-7163.MCT-12-0135. Epub 2012 Aug 28.

19.

Nutlin-3 cooperates with doxorubicin to induce apoptosis of human hepatocellular carcinoma cells through p53 or p73 signaling pathways.

Zheng T, Wang J, Song X, Meng X, Pan S, Jiang H, Liu L.

J Cancer Res Clin Oncol. 2010 Oct;136(10):1597-604. doi: 10.1007/s00432-010-0817-8. Epub 2010 Feb 20.

PMID:
20174822
20.
Items per page

Supplemental Content

Write to the Help Desk